Murine models of vascular thrombosis (Eitzman series)

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 27, Issue 10, 2007, Pages 2079-2093

  Westrick, Randal J ^a,c   Winn, Mary E ^b   Eitzman, Daniel T ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Animal models; Atherosclerosis; Mouse strains; Thrombosis; Vascular biology

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; FERRIC CHLORIDE; GELATINASE B; PRAVASTATIN; PROTEIN P53; ROSE BENGAL; SIMVASTATIN; ADRENALIN; COLLAGEN; FERRIC ION;

ALLELE; ANTIBODY SPECIFICITY; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BLOOD FLOW; FLUORESCENCE ANALYSIS; GENE INDUCTION; GENE OVEREXPRESSION; GENE TARGETING; HEART INFARCTION; HOMOZYGOSITY; KNOCKOUT MOUSE; LIGHT SCATTERING; LIPID DIET; NON INVASIVE MEASUREMENT; NONHUMAN; PHENOTYPIC VARIATION; PHOTOCHEMISTRY; PRIORITY JOURNAL; RABBIT; REPRODUCIBILITY; REVIEW; SCANNING ELECTRON MICROSCOPY; STRAIN DIFFERENCE; THROMBOGENESIS; TRANSGENIC MOUSE; VEIN INJURY; ANIMAL; ATHEROSCLEROSIS; BLOOD; BLOOD CLOTTING; BLOOD VESSEL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; FLUORESCENCE MICROSCOPY; GENETICS; GENOTYPE; INJURY; LASER; MICROSCOPY; MOUSE; PATHOPHYSIOLOGY; PHENOTYPE; SPECIES DIFFERENCE; THROMBOSIS;

ANIMALS; ATHEROSCLEROSIS; BLOOD COAGULATION; BLOOD VESSELS; COLLAGEN; DISEASE MODELS, ANIMAL; EPINEPHRINE; FERRIC COMPOUNDS; GENOTYPE; LASERS; MICE; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; MICROSCOPY, VIDEO; PHENOTYPE; REPRODUCIBILITY OF RESULTS; ROSE BENGAL; SPECIES SPECIFICITY; THROMBOSIS;

EID: 35148887056     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.107.142810     Document Type: Review

References (162)

1. Tofler GH, Massaro J, Levy D, Mittleman M, Sutherland P, Lipinska I, Muller JE, D'Agostino RB. Relation of the prothrombotic state to increasing age (from the Framingham Offspring Study). Am J Cardiol. 2005;96:1280-1283.
2. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O'Donnell C, Kittner S, Lloyd-Jones D, Goff DC Jr, Hong Y, Adams R, Friday G, Furie K, Gorelick P, Kissela B, Marler J, Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Wasserthiel-Smoller S, Wilson M, Wolf P. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85-e151.
3. Sun H. The interaction between pathogens and the host coagulation system. Physiology (Bethesda). 2006;21:281-288.
4. Souto JC, Almasy L, Borrell M, Gari M, Martinez E, Mateo J, Stone WH, Blangero J, Fontcuberta J. Genetic determinants of hemostasis phenotypes in Spanish families. Circulation. 2000;101:1546-1551.
5. Voetsch B, Loscalzo J. Genetic determinants of arterial thrombosis. Arterioscler Thromb Vasc Biol. 2004;24:216-229.
6. Hankey GJ. Potential new risk factors for ischemic stroke: what is their potential? Stroke. 2006;37:2181-2188.
7. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113:2363-2372.
8. Krumholz HM, Anderson JL, Brooks NH, Fesmire FM, Lambrew CT, Landrum MB, Weaver WD, Whyte J, Bonow RO, Bennett SJ, Burke G, Eagle KA, Linderbaum J, Masoudi FA, Normand SL, Pina IL, Radford MJ, Rumsfeld JS, Ritchie JL, Spertus JA. ACC/AHA clinical performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures on ST-Elevation and Non-ST-Elevation Myocardial Infarction). Circulation. 2006;113:732-761.
9. Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med. 1999;340:1555-1564.
10. Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT Jr, Raghunathan TE, Koepsell TD, Reitsma PH. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood. 1997;89:2817-2821.
11. Ginsburg D. Identifying novel genetic determinants of hemostatic balance. J Thromb Haemost. 2005;3:1561-1568.
12. Virchow RLK Thrombosis and Emboli. Canton, Mass: Science History Publications/USA; 1846.
13. Reimann-Hunziker G. Uber experimentelle Thrombose und ihre Behandlung mit Heparin. Schweizerische Medizinische Wochenschrift. 1944;74:66-69.
14. Didisheim P. Animal models useful in the study of thrombosis and antithrombotic agents. Prog Hemost Thromb. 1972;1:165-197.
15. Arfors KE, Dhall DP, Engeset J, Hint H, Matheson NA, Tangen O. In vivo quantitation of platelet activity using biolaser-induced endothelial injury. Bibl Anat. 1969;10:502-506.
16. Rosen ED, Raymond S, Zollman A, Noria F, Sandoval-Cooper M, Shulman A, Merz JL, Castellino FJ. Laser-induced noninvasive vascular injury models in mice generate platelet- and coagulation-dependent thrombi. Am J Pathol. 2001;158:1613-1622.
17. Denis C, Methia N, Frenette PS, Rayburn H, Ullman-Cullere M, Hynes RO, Wagner DD. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci U S A. 1998;95:9524-9529.
18. Frenette PS, Johnson RC, Hynes RO, Wagner DD. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc Natl Acad Sci U S A. 1995;92:7450-7454.
19. Falati S, Gross P, Merrill-Skoloff G, Furie BC, Furie B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med. 2002;8:1175-1181.
20. Flaumenhaft R, Tanaka E, Graham GJ, De Grand AM, Laurence RG, Hoshino K, Hajjar RJ, Frangioni JV. Localization and quantification of platelet-rich thrombi in large blood vessels with near-infrared fluorescence imaging. Circulation. 2007;115:84-93.
21. Day SM, Reeve JL, Myers DD, Fay WP. Murine thrombosis models. Thromb Haemost. 2004;92:486-494.
22. Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res. 1990;60:269-280.
23. Tseng MT, Dozier A, Haribabu B, Graham UM. Transendothelial migration of ferric ion in FeCl3 injured murine common carotid artery. Thromb Res. 2006;118:275-280.
24. Farrehi PM, Ozaki CK, Carmeliet P, Fay WP. Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation. 1998;97:1002-1008.
25. Wang X, Xu L. An optimized murine model of ferric chloride-induced arterial thrombosis for thrombosis research. Thromb Res. 2005;115:95-100.
26. Smyth SS, Reis ED, Vaananen H, Zhang W, Coller BS. Variable protection of beta 3-integrin-deficient mice from thrombosis initiated by different mechanisms. Blood. 2001;98:1055-1062.
27. Schlachterman A, Schuettrumpf J, Liu JH, Furlan Freguia C, Toso R, Poncz M, Camire RM, Arruda VR. Factor V Leiden improves in vivo hemostasis in murine hemophilia models. J Thromb Haemost. 2005;3:2730-2737.
28. Wang X, Smith PL, Hsu MY, Ogletree ML, Schumacher WA. Murine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor. J Thromb Haemost. 2006;4:403-410.
29. Wang X, Smith PL, Hsu MY, Tamasi JA, Bird E, Schumacher WA Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis. J Thromb Thrombolysis. 2006.
30. DiMinno G, Silver MJ. Mouse antithrombotic assay: a simple method for the evaluation of antithrombotic agents in vivo. Potentiation of antithrombotic activity by ethyl alcohol. J Pharmacol Exp Ther. 1983;225:57-60.
31. Furie BC, Furie B. Tissue factor pathway vs. collagen pathway for in vivo platelet activation. Blood Cells Mol Dis. 2006;36:135-138.
32. Singh R, Pan S, Mueske CS, Witt TA, Kleppe LS, Peterson TE, Caplice NM, Simari RD. Tissue factor pathway inhibitor deficiency enhances neointimal proliferation and formation in a murine model of vascular remodelling. Thromb Haemost. 2003;89:747-751.
33. Carmeliet P, Moons L, Collen D. Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis. Cardiovasc Res. 1998;39:8-33.
34. Sasaki T, Kuzuya M, Cheng XW, Nakamura K, Tamaya-Mori N, Maeda K, Kanda S, Koike T, Sato K, Iguchi A. A novel model of occlusive thrombus formation in mice. Lab Invest. 2004;84:1526-1532.
35. Henke PK, Pearce CG, Moaveni DM, Moore AJ, Lynch EM, Longo C, Varma M, Dewyer NA, Deatrick KB, Upchurch GR Jr, Wakefield TW, Hogaboam C, Kunkel SL. Targeted deletion of CCR2 impairs deep vein thombosis resolution in a mouse model. J Immunol. 2006;177:3388-3397.
36. Lindner V, Fingerle J, Reidy MA. Mouse model of arterial injury. Circ Res. 1993;73:792-796.
37. Roque M, Fallon JT, Badimon JJ, Zhang WX, Taubman MB, Reis ED. Mouse model of femoral artery denudation injury associated with the rapid accumulation of adhesion molecules on the luminal surface and recruitment of neutrophils. Arterioscler Thromb Vasc Biol. 2000;20:335-342.
38. Cheung WM, D'Andrea MR, Andrade-Gordon P, Damiano BP. Altered vascular injury responses in mice deficient in protease-activated receptor-1. Arterioscler Thromb Vasc Biol. 1999;19:3014-3024.
39. Pyo RT, Sato Y, Mackman N, Taubman MB. Mice deficient in tissue factor demonstrate attenuated intimal hyperplasia in response to vascular injury and decreased smooth muscle cell migration. Thromb Haemost. 2004;92:451-458.
40. Sullivan TR Jr, Karas RH, Aronovitz M, Faller GT, Ziar JP, Smith JJ, O'Donnell TF Jr, Mendelsohn ME. Estrogen inhibits the response-toinjury in a mouse carotid artery model. J Clin Invest. 1995;96:2482-2488.
41. Danenberg HD, Szalai AJ, Swaminathan RV, Peng L, Chen Z, Seifert P, Fay WP, Simon DI, Edelman ER. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation. 2003;108:512-515.
42. Vandeplassche G, Bernier M, Thone F, Borgers M, Kusama Y, Hearse DJ. Singlet oxygen and myocardial injury: ultrastructural, cytochemical and electrocardiographic consequences of photoactivation of rose bengal. J Mol Cell Cardiol. 1990;22:287-301.
43. Wilson CA, Hatchell DL. Photodynamic retinal vascular thrombosis. Rate and duration of vascular occlusion. Invest Ophthalmol Vis Sci. 1991;32:2357-2365.
44. Watson BD, Dietrich WD, Busto R, Wachtel MS, Ginsberg MD. Induction of reproducible brain infarction by photochemically initiated thrombosis. Ann Neurol. 1985;17:497-504.
45. Eitzman DT, Westrick RJ, Nabel EG, Ginsburg D. Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice. Blood. 2000;95:577-580.
46. Inamo J, Belougne E, Doutremepuich C. Importance of photo activation of rose bengal for platelet activation in experimental models of photochemically induced thrombosis. Thromb Res. 1996;83:229-235.
47. Ambrosio G, Tritto I, Golino P. Reactive oxygen metabolites and arterial thrombosis. Cardiovasc Res. 1997;34:445-452.
48. Matsuno H, Kozawa O, Niwa M, Ueshima S, Matsuo O, Collen D, Uematsu T. Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury. Thromb Haemost. 1999;81:601-604.
49. Matsuno H, Kozawa O, Okada K, Ueshima S, Matsuo O, Uematsu T. Plasmin generation plays different roles in the formation and removal of arterial and venous thrombus in mice. Thromb Haemost. 2002;87:98-104.
50. Bodary PF, Westrick RJ, Wickenheiser KJ, Shen Y, Eitzman DT. Effect of leptin on arterial thrombosis following vascular injury in mice. J Am Med Assoc. 2002;287:1706-1709.
51. Eitzman DT, Westrick RJ, Xu Z, Tyson J, Ginsburg D. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood. 2000;96:4212-4215.
52. Bodary PF, Vargas FB, King SA, Jongeward KL, Wickenheiser KJ, Eitzman DT. Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance. J Thromb Haemost. 2005;3:2149-2153.
53. Konstantinides S, Schafer K, Thinnes T, Loskutoff DJ. Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice. Circulation. 2001;103:576-583.
54. Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol. 2005;46:937-954.
55. Breslow JL. Mouse models of atherosclerosis. Science. 1996;272:685-688.
56. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb. 1994;14:133-140.
57. Eitzman DT, Westrick RJ, Xu Z, Tyson J, Ginsburg D. Hyperlipidemia promotes thrombosis after injury to atherosclerotic vessels in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2000;20:1831-1834.
58. Westrick RJ, Bodary PF, Xu Z, Shen YC, Broze GJ, Eitzman DT. Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice. Circulation. 2001;103:3044-3046.
59. Cui J, Eitzman DT, Westrick RJ, Christie PD, Xu ZJ, Yang AY, Purkayastha AA, Yang TL, Metz AL, Gallagher KP, Tyson JA, Rosenberg RD, Ginsburg D. Spontaneous thrombosis in mice carrying the factor V Leiden mutation. Blood. 2000;96:4222-4226.
60. Yin ZF, Huang ZF, Cui J, Fiehler R, Lasky N, Ginsburg D, Broze GJ Jr. Prothrombotic phenotype of protein Z deficiency. Proc Natl Acad Sci U S A. 2000;97:6734-6738.
61. Eitzman DT, Westrick RJ, Bi X, Manning SL, Wilkinson JE, Broze GJ, Ginsburg D. Lethal perinatal thrombosis in mice resulting from the interaction of tissue factor pathway inhibitor deficiency and factor V Leiden. Circulation. 2002;105:2139-2142.
62. Mackman N. Tissue-specific hemostasis in mice. Arterioscler Thromb Vasc Biol. 2005;25:2273-2281.
63. Rosen ED, Xuei X, Suckow M, Edenberg H. Searching for hemostatic modifier genes affecting the phenotype of mice with very low levels of FVII. Blood Cells Mol Dis. 2006;36:131-134.
64. Hoover-Plow JL, Shchurin A, Hart E, Sha J, Singer JB, Hill AE, Nadeau JH. Genetic Background Determines Response to Hemostasis and Thrombosis. BMC Blood Disord. 2006;6:6.
65. Singer JB, Hill AE, Burrage LC, Olszens KR, Song J, Justice M, O'Brien WE, Conti DV, Witte JS, Lander ES, Nadeau JH. Genetic dissection of complex traits with chromosome substitution strains of mice. Science. 2004;304:445-448.
66. Hathcock JJ. Flow effects on coagulation and thrombosis. Arterioscler Thromb Vasc Biol. 2006;26:1729-1737.
67. Aird WC. Endothelial cell heterogeneity. Crit Care Med. 2003;31:S221-230.
68. Chou J, Mackman N, Merrill-Skoloff G, Pedersen B, Furie BC, Furie B. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood. 2004;104:3190-3197.
69. Day SM, Reeve JL, Pedersen B, Farris DM, Myers DD, Im M, Wakefield TW, Mackman N, Fay WP. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood. 2005;105:192-198.
70. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, Chesebro JH, Badimon L, Nemerson Y, Fuster V, Badimon JJ. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation. 1997;95:594-599.
71. Wilson KM, Lynch CM, Faraci FM, Lentz SR. Effect of mechanical ventilation on carotid artery thrombosis induced by photochemical injury in mice. J Thromb Haemost. 2003;1:2669-2674.
72. He L, Vicente CP, Westrick RJ, Eitzman DT, Tollefsen DM. Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J Clin Invest. 2002;109:213-219.
73. Silver L. Mouse Genetics, Concepts and Applications. New York: Oxford University Press, Inc.; 1995.
74. Sigmund CD. Viewpoint: are studies in genetically altered mice out of control? Arterioscler Thromb Vasc Biol. 2000;20:1425-1429.
75. Wong GT. Speed congenics: applications for transgenic and knock-out mouse strains. Neuropeptides. 2002;36:230-236.
76. Takeshita K, Yamamoto K, Ito M, Kondo T, Matsushita T, Hirai M, Kojima T, Nishimura M, Nabeshima Y, Loskutoff DJ, Saito H, Murohara T. Increased expression of plasminogen activator inhibitor-1 with fibrin deposition in a murine model of aging, "Klotho" mouse. Semin Thromb Hemost. 2002;28:545-554.
77. Yamamoto K, Shimokawa T, Yi H, Isobe K, Kojima T, Loskutoff DJ, Saito H. Aging and obesity augment the stress-induced expression of tissue factor gene in the mouse. Blood. 2002;100:4011-4018.
78. Yamamoto K, Takeshita K, Shimokawa T, Yi H, Isobe K, Loskutoff DJ, Saito H. Plasminogen activator inhibitor-1 is a major stress-regulated gene: implications for stress-induced thrombosis in aged individuals. Proc Natl Acad Sci U S A. 2002;99:890-895.
79. Shen Y, Bodary PF, Vargas FB, Homeister JW, Gordon D, Ostenso KA, Shayman JA, Eitzman DT. Alpha-galactosidase A deficiency leads to increased tissue fibrin deposition and thrombosis in mice homozygous for the factor V Leiden mutation. Stroke. 2006;37:1106-1108.
80. Peters LL, Zhang W, Lambert AJ, Brugnara C, Churchill GA, Platt OS. Quantitative trait loci for baseline white blood cell count, platelet count, and mean platelet volume. Mamm Genome. 2005;16:749-763.
81. Fry RJ, Hamilton KH, Lisco H. Thrombi in the left atrium of the heart in mice. Arch Pathol. 1965;80:308-313.
82. Constien R, Forde A, Liliensiek B, Grone HJ, Nawroth P, Hammerling G, Arnold B. Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line. Genesis. 2001;30:36-44.
83. Koni PA, Joshi SK, Temann UA, Olson D, Burkly L, Flavell RA. Conditional vascular cell adhesion molecule 1 deletion in mice: impaired lymphocyte migration to bone marrow. J Exp Med. 2001;193:741-754.
84. Sakuraba Y, Sezutsu H, Takahasi KR, Tsuchihashi K, Ichikawa R, Fujimoto N, Kaneko S, Nakai Y, Uchiyama M, Goda N, Motoi R, Ikeda A, Karashima Y, Inoue M, Kaneda H, Masuya H, Minowa O, Noguchi H, Toyoda A, Sakaki Y, Wakana S, Noda T, Shiroishi T, Gondo Y. Molecular characterization of ENU mouse mutagenesis and archives. Biochem Biophys Res Commun. 2005;336:609-616.
85. Cordes SP. N-ethyl-N-nitrosourea mutagenesis: boarding the mouse mutant express. Microbiol Mol Biol Rev. 2005;69:426-439.
86. Quwailid MM, Hugill A, Dear N, Vizor L, Wells S, Horner E, Fuller S, Weedon J, McMath H, Woodman P, Edwards D, Campbell D, Rodger S, Carey J, Roberts A, Glenister P, Lalanne Z, Parkinson N, Coghill EL, McKeone R, Cox S, Willan J, Greenfield A, Keays D, Brady S, Spurr N, Gray I, Hunter J, Brown SD, Cox RD. A gene-driven ENU-based approach to generating an allelic series in any gene. Mamm Genome. 2004;15:585-591.
87. Vivian JL, Chen Y, Yee D, Schneider E, Magnuson T. An allelic series of mutations in Smad2 and Smad4 identified in a genotype-based screen of N-ethyl-N- nitrosourea-mutagenized mouse embryonic stem cells. Proc Natl Acad Sci U S A. 2002;99:15542-15547.
88. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Jirouskova M, Degen JL. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 2005;105:178-185.
89. Eitzman DaW, RJ. Vascular Photochemical Injury in the Mouse. In: Rogers DISaC, ed. Contemporary Cardiology: Vascular Disease and Injury: Preclinical Research. Totowa, NJ: Humana Press Inc.; 2000.
90. Bodary PF, Shen Y, Ohman M, Bahrou KL, Vargas FB, Cudney SS, Wickenheiser KJ, Myers MG Jr, Eitzman DT. Leptin regulates neointima formation after arterial injury through mechanisms independent of blood pressure and the leptin receptor/STAT3 signaling pathways involved in energy balance. Arterioscler Thromb Vasc Biol. 2007;27:70-76.
91. Schafer K, Muller K, Hecke A, Mounier E, Goebel J, Loskutoff DJ, Konstantinides S. Enhanced thrombosis in atherosclerosis-prone mice is associated with increased arterial expression of plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol. 2003;23:2097-2103.
92. Enjyoji K, Sevigny J, Lin Y, Frenette PS, Christie PD, Esch JS 2nd, Imai M, Edelberg JM, Rayburn H, Lech M, Beeler DL, Csizmadia E, Wagner DD, Robson SC, Rosenberg RD. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med. 1999;5:1010-1017.
93. Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, Phillips DR, Wagner DD. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med. 2002;8:247-252.
94. Dubois C, Panicot-Dubois L, Merrill-Skoloff G, Furie B, Furie BC. Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo. Blood. 2006;107:3902-3906.
95. Wang X, Cheng Q, Xu L, Feuerstein GZ, Hsu MY, Smith PL, Seiffert DA, Schumacher WA, Ogletree ML, Gailani D. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost. 2005;3:695-702.
96. Matuskova J, Chauhan AK, Cambien B, Astrof S, Dole VS, Piffath CL, Hynes RO, Wagner DD. Decreased plasma fibronectin leads to delayed thrombus growth in injured arterioles. Arterioscler Thromb Vasc Biol. 2006;26:1391-1396.
97. Renne T, Pozgajova M, Gruner S, Schuh K, Pauer HU, Burfeind P, Gailani D, Nieswandt B. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med. 2005;202:271-281.
98. Erhardt JA, Toomey JR, Douglas SA, Johns DG. P2X1 stimulation promotes thrombin receptor-mediated platelet aggregation. J Thromb Haemost. 2006;4:882-890.
99. Sakurai K, Matsuo Y, Sudo T, Takuwa Y, Kimura S, Kasuya Y. Role of p38 mitogen-activated protein kinase in thrombus formation. J Recept Signal Transduct Res. 2004;24:283-296.
100. Weiss EJ, Hamilton JR, Lease KE, Coughlin SR. Protection against thrombosis in mice lacking PAR3. Blood. 2002;100:3240-3244.
101. Yokoyama S, Ikeda H, Haramaki N, Yasukawa H, Murohara T, Imaizumi T. Platelet P-selectin plays an important role in arterial thrombogenesis by forming large stable platelet-leukocyte aggregates. J Am Coll Cardiol. 2005;45:1280-1286.
102. Chrzanowska-Wodnicka M, Smyth SS, Schoenwaelder SM, Fischer TH, White GC 2nd. Rap1b is required for normal platelet function and hemostasis in mice. J Clin Invest. 2005;115:680-687.
103. Reheman A, Gross P, Yang H, Chen P, Allen D, Leytin V, Freedman J, Ni H. Vitronectin stabilizes thrombi and vessel occlusion but plays a dual role in platelet aggregation. J Thromb Haemost. 2005;3:875-883.
104. Ni H, Denis CV, Subbarao S, Degen JL, Sato TN, Hynes RO, Wagner DD. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest. 2000;106:385-392.
105. Pozgajova M, Sachs UJ, Hein L, Nieswandt B. Reduced thrombus stability in mice lacking the alpha2A-adrenergic receptor. Blood. 2006;108:510-514.
106. Eslin DE, Zhang C, Samuels KJ, Rauova L, Zhai L, Niewiarowski S, Cines DB, Poncz M, Kowalska MA. Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin. Blood. 2004;104:3173-3180.
107. Lian L, Wang Y, Draznin J, Eslin D, Bennett JS, Poncz M, Wu D, Abrams CS. The relative role of PLCbeta and PI3Kgamma in platelet activation. Blood. 2005;106:110-117.
108. Luttun A, Lupu F, Storkebaum E, Hoylaerts MF, Moons L, Crawley J, Bono F, Poole AR, Tipping P, Herbert JM, Collen D, Carmeliet P. Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2002;22:499-505.
109. Angelillo-Scherrer A, de Frutos P, Aparicio C, Melis E, Savi P, Lupu F, Arnout J, Dewerchin M, Hoylaerts M, Herbert J, Collen D, Dahlback B, Carmeliet P. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med. 2001;7:215-221.
110. He L, Pappan LK, Grenache DG, Li Z, Tollefsen DM, Santoro SA, Zutter MM. The contributions of the alpha 2 beta 1 integrin to vascular thrombosis in vivo. Blood. 2003;102:3652-3657.
111. Nonne C, Lenain N, Hechler B, Mangin P, Cazenave JP, Gachet C, Lanza F. Importance of platelet phospholipase Cgamma2 signaling in arterial thrombosis as a function of lesion severity. Arterioscler Thromb Vasc Biol. 2005;25:1293-1298.
112. Hechler B, Lenain N, Marchese P, Vial C, Heim V, Freund M, Cazenave JP, Cattaneo M, Ruggeri ZM, Evans R, Gachet C. A role of the fast ATP-gated P2X1 cation channel in thrombosis of small arteries in vivo. J Exp Med. 2003;198:661-667.
113. Falati S, Liu Q, Gross P, Merrill-Skoloff G, Chou J, Vandendries E, Celi A, Croce K, Furie BC, Furie B. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med. 2003;197:1585-1598.
114. Nieswandt B, Schulte V, Bergmeier W, Mokhtari-Nejad R, Rackebrandt K, Cazenave JP, Ohlmann P, Gachet C, Zirngibl H. Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. J Exp Med. 2001;193:459-469.
115. Leon C, Hechler B, Freund M, Eckly A, Vial C, Ohlmann P, Dierich A, LeMeur M, Cazenave JP, Gachet C. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Invest. 1999;104:1731-1737.
116. Ni H, Ramakrishnan V, Ruggeri ZM, Papalia JM, Phillips DR, Wagner DD. Increased thrombogenesis and embolus formation in mice lacking glycoprotein V. Blood. 2001;98:368-373.
117. Peng L, Mundada L, Stomel JM, Liu JJ, Sun J, Yet SF, Fay WP. Induction of heme oxygenase-1 expression inhibits platelet-dependent thrombosis. Antioxid Redox Signal. 2004;6:729-735.
118. Murata T, Ushikubi F, Matsuoka T, Hirata M, Yamasaki A, Sugimoto Y, Ichikawa A, Aze Y, Tanaka T, Yoshida N, Ueno A, Oh-ishi S, Narumiya S. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature. 1997;388:678-682.
119. Falati S, Patil S, Gross PL, Stapleton M, Merrill-Skoloff G, Barrett NE, Pixton KL, Weiler H, Cooley B, Newman DK, Newman PJ, Furie BC, Furie B, Gibbins JM. Platelet PECAM-1 inhibits thrombus formation in vivo. Blood. 2006;107:535-541.
120. Weiler H, Lindner V, Kerlin B, Isermann BH, Hendrickson SB, Cooley BC, Meh DA, Mosesson MW, Shworak NW, Post MJ, Conway EM, Ulfman LH, von Andrian UH, Weitz JI. Characterization of a mouse model for thrombomodulin deficiency. Arterioscler Thromb Vasc Biol. 2001;21:1531-1537.
121. Dorffler-Melly J, de Kruif M, Schwarte LA, Franco RF, Florquin S, Spek CA, Ince C, Reitsma PH, ten Cate H. Functional thrombomodulin deficiency causes enhanced thrombus growth in a murine model of carotid artery thrombosis. Basic Res Cardiol. 2003;98:347-352.
122. Fay WP, Parker AC, Ansari MN, Zheng X, Ginsburg D. Vitronectin inhibits the thrombotic response to arterial injury in mice. Blood. 1999;93:1825-1830.
123. Chauhan AK, Motto DG, Lamb CB, Bergmeier W, Dockal M, Plaimauer B, Scheiflinger F, Ginsburg D, Wagner DD. Systemic antithrombotic effects of ADAMTS13. J Exp Med. 2006;203:767-776.
124. Bodary PF, Gu S, Shen Y, Hasty AH, Buckler JM, Eitzman DT. Recombinant leptin promotes atherosclerosis and thrombosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2005;25:e119-122.
125. Dayal S, Wilson KM, Leo L, Arning E, Bottiglieri T, Lentz SR. Enhanced susceptibility to arterial thrombosis in a murine model of hyperhomocysteinemia. Blood. 2006;108:2237-2243.
126. Eitzman DT, Westrick RJ, Shen Y, Bodary PF, Gu S, Manning SL, Dobies SL, Ginsburg D. Homozygosity for factor V Leiden leads to enhanced thrombosis and atherosclerosis in mice. Circulation. 2005;111:1822-1825.
127. Eitzman DT, Bodary PF, Shen Y, Khairallah CG, Wild SR, Abe A, Shaffer-Hartman J, Shayman JA. Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis. J Am Soc Nephrol. 2003;14:298-302.
128. Ijiri Y, Miura M, Hashimoto M, Fukunaga C, Watanabe S, Kubota A, Oiwa K, Okuda T, Yamamoto J. A new model to evaluate the diet-induced prothrombotic state, using He-Ne laser-induced thrombogenesis in the carotid artery of apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. Blood Coagul Fibrinolysis. 2002;13:497-504.
129. Kato H, Kashiwagi H, Shiraga M, Tadokoro S, Kamae T, Ujiie H, Honda S, Miyata S, Ijiri Y, Yamamoto J, Maeda N, Funahashi T, Kurata Y, Shimomura I, Tomiyama Y, Kanakura Y. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol. 2006;26:224-230.
130. Banno F, Kokame K, Okuda T, Honda S, Miyata S, Kato H, Tomiyama Y, Miyata T. Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood. 2006;107:3161-3166.
131. Hechler B, Zhang Y, Eckly A, Cazenave JP, Gachet C, Ravid K. Lineage-specific overexpression of the P2Y1 receptor induces platelet hyper-reactivity in transgenic mice. J Thromb Haemost. 2003;1:155-163.
132. Ma H, Hara A, Xiao CY, Okada Y, Takahata O, Nakaya K, Sugimoto Y, Ichikawa A, Narumiya S, Ushikubi F. Increased bleeding tendency and decreased susceptibility to thromboembolism in mice lacking the prostaglandin E receptor subtype EP(3). Circulation. 2001;104:1176-1180.
133. Sasaki T, Kuzuya M, Nakamura K, Cheng XW, Shibata T, Sato K, Iguchi A. A simple method of plaque rupture induction in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2006;26:1304-1309.
134. Shimshi M, Abe E, Fisher EA, Zaidi M, Fallon JT. Bisphosphonates induce inflammation and rupture of atherosclerotic plaques in apolipoprotein-E null mice. Biochem Biophys Res Commun. 2005;328:790-793.
135. Gough PJ, Gomez IG, Wille PT, Raines EW. Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J Clin Invest. 2006;116:59-69.
136. Reddick RL, Zhang SH, Maeda N. Aortic atherosclerotic plaque injury in apolipoprotein E deficient mice. Atherosclerosis. 1998;140:297-305.
137. von der Thusen JH, van Vlijmen BJ, Hoeben RC, Kockx MM, Havekes LM, van Berkel TJ, Biessen EA. Induction of atherosclerotic plaque rupture in apolipoprotein E-/- mice after adenovirus-mediated transfer of p53. Circulation. 2002;105:2064-2070.
138. Johnson JL, Jackson CL. Atherosclerotic plaque rupture in the apolipoprotein E knockout mouse. Atherosclerosis. 2001;154:399-406.
139. Rosenfeld ME, Polinsky P, Virmani R, Kauser K, Rubanyi G, Schwartz SM. Advanced atherosclerotic lesions in the innominate artery of the ApoE knockout mouse. Arterioscler Thromb Vasc Biol. 2000;20:2587-2592.
140. Williams H, Johnson JL, Carson KG, Jackson CL. Characteristics of intact and ruptured atherosclerotic plaques in brachiocephalic arteries of apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 2002;22:788-792.
141. Calara F, Silvestre M, Casanada F, Yuan N, Napoli C, Palinski W. Spontaneous plaque rupture and secondary thrombosis in apolipoprotein E-deficient and LDL receptor-deficient mice. J Pathol. 2001;195:257-263.
142. Bea F, Blessing E, Bennett B, Levitz M, Wallace EP, Rosenfeld ME. Simvastatin promotes atherosclerotic plaque stability in apoE-deficient mice independently of lipid lowering. Arterioscler Thromb Vasc Biol. 2002;22:1832-1837.
143. Johnson J, Carson K, Williams H, Karanam S, Newby A, Angelini G, George S, Jackson C. Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse: model characterization and effects of pravastatin treatment. Circulation. 2005;111:1422-1430.
144. Li TT, Larrucea S, Souza S, Leal SM, Lopez JA, Rubin EM, Nieswandt B, Bray PF. Genetic variation responsible for mouse strain differences in integrin alpha 2 expression is associated with altered platelet responses to collagen. Blood. 2004;103:3396-3402.
145. Degen JL, Drew AF, Palumbo JS, Kombrinck KW, Bezerra JA, Danton MJ, Holmback K, Suh TT. Genetic manipulation of fibrinogen and fibrinolysis in mice. Ann N Y Acad Sci. 2001;936:276-290.
146. Toomey JR, Kratzer KE, Lasky NM, Broze GJ Jr. Effect of tissue factor deficiency on mouse and tumor development. Proc Natl Acad Sci U S A. 1997;94:6922-6926.
147. Motto DG, Chauhan AK, Zhu G, Homeister J, Lamb CB, Desch KC, Zhang W, Tsai HM, Wagner DD, Ginsburg D. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest. 2005;115:2752-2761.
148. Kawasaki T, Taniguchi M, Moritani Y, Uemura T, Shigenaga T, Takamatsu H, Hayashi K, Takasaki J, Saito T, Nagai K. Pharmacological properties of YM-254890, a specific G(alpha)q/11 inhibitor, on thrombosis and neointima formation in mice. Thromb Haemost. 2005;94:184-192.
149. Rusconi CP, Roberts JD, Pitoc GA, Nimjee SM, White RR, Quick G Jr, Scardino E, Fay WP, Sullenger BA. Antidote-mediated control of an anticoagulant aptamer in vivo. Nat Biotechnol. 2004;22:1423-1428.
150. Lindenblatt N, Schareck W, Belusa L, Nickels RM, Menger MD, Vollmar B. Anti-oxidant ebselen delays microvascular thrombus formation in the rat cremaster muscle by inhibiting platelet P-selectin expression. Thromb Haemost. 2003;90:882-892.
151. Iwatsuki Y, Kawasaki T, Hayashi K, Moritani Y, Nii T, Miyata K. Combined effects of a factor Xa inhibitor YM466 and a GPIIb/IIIa antagonist YM128 on thrombosis and neointima formation in mice. Thromb Haemost. 2004;92:1221-1228.
152. Schwarz M, Meade G, Stoll P, Ylanne J, Bassler N, Chen YC, Hagemeyer CE, Ahrens I, Moran N, Kenny D, Fitzgerald D, Bode C, Peter K. Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets. Circ Res. 2006;99:25-33.
153. Kondo K, Suzuki Y, Ikeda Y, Umemura K. Genistein, an isoflavone included in soy, inhibits thrombotic vessel occlusion in the mouse femoral artery and in vitro platelet aggregation. Eur J Pharmacol. 2002;455:53-57.
154. Cheng J, Kondo K, Suzuki Y, Ikeda Y, Meng X, Umemura K. Inhibitory effects of total flavones of Hippophae Rhamnoides L on thrombosis in mouse femoral artery and in vitro platelet aggregation. Life Sci. 2003;72:2263-2271.
155. Matsuno H, Kozawa O, Ueshima S, Matsuo O, Collen D, Uematsu T. Lack of tPA significantly affects antithrombotic therapy by a GPIIb/IIIa antagonist, but not by a thrombin inhibitor in mice. Thromb Haemost. 2000;83:605-609.
156. Matsuno H, Kozawa O, Okada K, Ueshima S, Matsuo O, Uematsu T. Inhibitors of fibrinolytic components play different roles in the formation and removal of arterial thrombus in mice. J Cardiovasc Pharmacol. 2002;39:278-286.
157. Nishida M, Matsuno H, Kozawa O, Ueshima S, Matsuo O, Collen D, Uematsu T. tPA, but not uPA, significantly affects antithrombotic therapy by a glycoprotein IIb/IIIa antagonist, but not by a factor Xa inhibitor. J Cardiovasc Pharmacol. 2000;36:770-775.
158. Vicente CP, He L, Pavao MS, Tollefsen DM. Antithrombotic activity of dermatan sulfate in heparin cofactor II-deficient mice. Blood. 2004;104:3965-3970.
159. Hechler B, Magnenat S, Zighetti ML, Kassack MU, Ullmann H, Cazenave JP, Evans R, Cattaneo M, Gachet C. Inhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF449 [4,4′,4″,4‴-(carbonylbis(imino-5,1, 3-benzenetriylbis-(carbonylimino)))t etrakisbenzene-1,3-disulfonic acid octasodium salt]. J Pharmacol Exp Ther. 2005;314:232-243.
160. Sorg H, Hoffmann JN, Menger MD, Lindenblatt N, Goehring P, Vollmar B. Antithrombin is as effective as heparin and hirudin to prevent formation of microvascular thrombosis in a murine model. Thromb Haemost. 2006;96:371-377.
161. Thorlacius H, Vollmar B, Seyfert UT, Vestweber D, Menger MD. The polysaccharide fucoidan inhibits microvascular thrombus formation independently from P- and L-selectin function in vivo. Eur J Clin Invest. 2000;30:804-810.
162. Maurice P, Pires V, Amant C, Kauskot A, Da Nascimento S, Sonnet P, Rochette J, Legrand C, Fauvel-Lafeve F, Bonnefoy A. Antithrombotic effect of the type III collagen-related octapeptide (KOGEOGPK) in the mouse. Vascul Pharmacol. 2006;44:42-49.